Lv2
146 积分 2021-08-10 加入
Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies
4小时前
待确认
Encoding BRAF Inhibitor Functions in Protein Degraders
25天前
已完结
The Myocyte Enhancer Factor 2C (MEF2C) Is a Direct Transcriptional Target of HOXA9 and Mediates Leukemia Survival in Human Mixed-Lineage Leukemias
1个月前
已关闭
Myocyte enhancer factor 2C in hematopoiesis and leukemia
1个月前
已完结
Structural basis of tolvaptan binding to the vasopressin V2 receptor
1个月前
已完结
Discovery of a Potent, Highly Selective, and In Vivo Anti-inflammatory Efficacious, P2Y6R Antagonist with a Novel Quinoline-pyrazole Scaffold
1个月前
已完结
Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms
1个月前
已完结
Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study
1个月前
已完结
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study
1个月前
已完结
FGF amplification an important targeted for head and neck cancer patient? A case report of a patient with FGF amplification treated with erdafitinib
1个月前
已完结
皖公网安备34019202002308
